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The dysregulation of the relationship between gut microbiota and innate immune homeostasis can
lead to a range of complex diseases. In this issue, Man et al. reveal that the intracellular innate
sensor AIM2 regulates microbial and stem cell homeostasis in the gut to protect against colorectal
cancer.‘‘Cancer is a word, not a sentence.’’
These are the inspiring words of John Dia-
mond, the British broadcaster and jour-
nalist who succumbed to cancer in
2001. In his memoir, a witty and moving
account of his fight with cancer he wrote,
‘‘What can the chances be of any organ
doing anything a billion and a half times
and never making a mistake?’’ He ques-
tions what keeps our myriad of inces-
santly replicating cells from joining
together in a state of ‘‘cellular anarchy’’
that can cause cancer. Although the
answer to this question remains a com-
plex multifactorial puzzle, the past few
years have seen a surge in studies
exploring the intimate link between the
innate immune system, microbiota, and
cancer. In this context, Man et al. (2015)
(this issue of Cell) now identify a role for
the innate immune sensor Absent in
Melanoma 2 (AIM2) in inhibiting the devel-
opment of colon cancer by controlling
intestinal stem cell proliferation and regu-
lating the gut microbiota.
Colon cancer is the second leading
cause of cancer death in the United
States. However, the underlying mecha-
nisms that either predispose individuals
to or promote development of colorectal
cancer remain poorly understood. Aber-
rant expression of several innate immune
sensors, including Toll-like receptors
(TLRs) and NOD-like receptors (NLRs),
is highly associated with cancers at bar-
rier sites, particularly the intestinal mu-
cosa (Luddy et al., 2014). In particular,
NLRC4, NLRP3, NLRP6, and NLRP12
have been implicated in protection
against colitis-associated colorectal can-
cer (CAC) by preserving the integrity of
the epithelial barrier, checking altered
cell signaling, and/or regulating the
composition of microbiota colonizing the18 Cell 162, July 2, 2015 ª2015 Elsevier Inc.intestine (Janowski et al., 2013). Although
protective in some circumstances, acti-
vation of innate sensors—particularly
TLR4—can have detrimental effects.
Indeed, the role of innate immunity in
colorectal cancer stems from the recogni-
tion that inflammation is a major driver of
carcinogenesis. Pro-inflammatory cyto-
kines such as IL-1b, TNF-a, and IL-6 are
released following activation of the innate
immune response and are linked to
neoplastic transformation in CAC. Addi-
tionally, several NLRs are heterogeneous
in their expression and can regulate
diverse biological processes beyond
inflammation and tissue homeostasis
to include autophagy, transcription, and
cellular development (Kufer and Sanso-
netti, 2011), suggesting that, in the
context of a complex disease like cancer,
innate sensors may exert multiple and
disparate or combinatorial, cell-type-spe-
cific effects.
AIM2 was initially characterized as a
gene that is upregulated upon melanoma
tumor reversion (DeYoung et al., 1997).
Subsequent in vitro work identified a pro-
tective role for AIM2 in breast and colon
cancer (Patsos et al., 2010). AIM2 became
an area of intense research focus after its
recognition as a double-stranded DNA
sensor in the host cell cytosol, capable of
forming an oligomeric signaling complex
called the inflammasome that activates
caspase-1, leading to release of the pro-
inflammatory cytokines IL-1b and IL-18
(Fernandes-Alnemri et al., 2009; Hornung
et al., 2009). Clinically, the absence of
AIM2 is associated with tumorigenesis;
colon cancer patients exhibit reduced
expression of Aim2, and lower expression
correlates with a poor prognosis (Dihl-
mann et al., 2014). To gain insight into
the role of AIM2 in colon cancer, Manet al. (2015) employ a model of azoxy-
methane (AOM) and dextran sulfate so-
dium (DSS)-induced colorectal cancer in
WT and Aim2/ mice. Aim2/ animals
exhibit greater tumor burden yet no
difference in inflammasome-dependent
cytokines at day14andday80post-expo-
sure to AOM and DSS. Caspase-1/
and Asc/ mice exhibit a significantly
reduced inflammatory response, suggest-
ing that tumor progression mediated by
lack of AIM2 is independent of its role in in-
flammasome activation. Whether AIM2-
or NLR-mediated activation of the inflam-
masome is involved in limiting initial tumor
formation remains open to question.
Irrespective of its role in inflammasome
activation, previous reports have identi-
fied a role for AIM2 in inducing cell-cycle
arrest in colon cancer cells (Patsos et al.,
2010). Man et al. (2015) demonstrate
that AIM2 exerts its function by inhibiting
cellular proliferation, as the colons of
Aim2/ mice exhibit greater numbers
of Ki67+ and BrdU+ cells and a global
upregulation of proliferation-associated
genes. Aim2/ colons also contained
higher levels of activated AKT, a cell sur-
vival factor, and inactivated PTEN, a tu-
mor suppressor that negatively regulates
the AKT pathway (Figure 1). This corre-
lates with increased expression of the
proto-oncogene c-Myc that promotes
cell proliferation and transformation.
Collectively, these data suggest that
AIM2may itself act as a tumor suppressor
that, via yet-unknown mechanism(s),
limits tumor cell proliferation by repres-
sing proto-oncogenes and the AKT
pathway. Loss of AIM2 also restricts the
activation of pro-apoptotic factors cas-
pase-3 and caspase-7 to limit cell death
that may in turn contribute to increased
cell proliferation (Figure 1).
Figure 1. Role of AIM2 in Protection against Tumorigenesis
Decreased expression of the gene encoding AIM2 is linked to increased tumor
growth and mortality in colorectal cancer patients. In a colitis-associated
tumorigenesis model involving exposure to azoxymethane (AOM) and dextran
sulfate sodium (DSS), WT mice (top) show decreased expression of Aim2 and
modest tumor growth in the colon. This is regulated by restriction of the AKT
pathway by the tumor suppressor PTEN and increased activation of pro-
apoptotic factors CASP3 and CASP7. In contrast, Aim2/ mice (bottom)
show rapid tumor growth promoted by expansion of Prom1+ intestinal stem
cells in response to aberrant Wnt/b-catenin signaling. Through yet-unknown
attributes, the loss of AIM2 results in the inactivation of PTEN via its phos-
phorylation, leading to activation (phosphorylation) of AKT and increased
expression of genes involved in cell proliferation and tumorigenesis, including
c-Myc. Aim2/mice also exhibit a modified microbiota composed of species
linked to increased tumor development, further amplifying their susceptibility
to colorectal tumorigenesis. Altered homeostatic microbiota and aberrant AKT
and b-catenin signaling may thus act in concert to promote tumorigenesis
resulting from loss of AIM2.AIM2, like many innate sen-
sors, is fairly ubiquitous within
host cells. Man et al. (2015)
show that, in the context
of regulating colorectal can-
cer, AIM2 functions mainly
within the non-hematopoietic
compartment but also to
some degree within the
hematopoietic compartment.
The mechanism by which he-
matopoietic AIM2 contributes
to colorectal tumorigenesis
remains undefined, but it is
reasonable to hypothesize
that AIM2 has distinct func-
tional roles in the hematopoi-
etic and non-hematopoietic
nicheandpossiblyvaried roles
in different cell types consti-
tuting these niches. Previous
work has demonstrated that
intestinal stem cells are the
cellsoforigin for intestinal can-
cers (Barker et al., 2009) and
are particularly vulnerable to
tumors induced by activating
mutations in b-catenin. Us-
ing Aim2/ mice expressing
tamoxifen-inducible, aberrant
Wnt/b-catenin signaling in
Prom1+ stem cells, Man et al.
(2015) demonstrate that
AIM2 limits Prom1+ stem cell
proliferation. Compared to
WT mice, Aim2/ mice
have increased numbers of
Prom1+ cells in the intestine
that correlate with increased
activation of AKT and expres-
sion of Ki67 and c-Myc
(Figure 1).Modest cellular pro-
liferation is also observed in
wild-type (WT) mice, which
may correspond with down-
regulation of Aim2 following
exposure to carcinogens.
Further research is required
to elucidate how Aim2 is
downregulated in the intestine
during development of can-cer. The possibilities are various, ranging
from direct or indirect transcriptional inhi-
bition of AIM2 by a putative inhibitor to
regulation of RNA stability by non-coding
RNAs. The gut microenvironment is com-
plex, and it is likely that combinatorial
signaling cascades triggered by both mi-crobiota-derived and endogenous ligands
trigger this downregulation.
Intestinal cells engage with gut micro-
biota in an intimate crosstalk that is
believed to regulate inflammation, cell
proliferation, and development. There-
fore, Man et al. (2015) further investigateCell 162, Julythe role of microbiota in
the susceptibility of Aim2/
mice to tumorigenesis. Inter-
estingly, Aim2/mice exhibit
an altered microbiota, con-
taining bacterial species pre-
viously linked to colon cancer.
Co-housing WT and Aim2/
mice decreased the tumor
burden in Aim2/ animals,
an observation that raises
the possibility of microbiota
engraftment as a preventive
measure for reducing the risk
of developing CAC resulting
from loss-of-function muta-
tions in AIM2. Of interest and
yet to be studied is the causal
relationship between lack of
AIM2, increased cellular pro-
liferation, and dysbiotic gut
microbiota; nevertheless, the
loss of AIM2 appears to elicit
intrinsic immune mechanisms




modified ligands such as
microbe-associated molecu-
lar patterns and metabolites
produced by gut microbiota
or altered tumor antigens
and danger signals released
from host cells may further
contribute to aberrant cell
signaling and tumorigenesis
in the Aim2/ environment
compared to the WT envi-
ronment. Man et al. (2015)
observe that tumor burden
is modestly increased in WT
mice co-housed with Aim2/
mice when compared to
singly-housed WT mice,
indicating that dysregulation
of the microbiota, at least
in part, contributes to
increased cellular prolifera-
tion and overall suggesting a
complex link between thecomposition of gut microbiota and dysre-
gulation of cellular homeostasis leading to
tumorigenesis.
Although it is tentative to suggest
modulation of AIM2 as a treatment
for colorectal cancer, it must be done
with caution. Most innate sensors with2, 2015 ª2015 Elsevier Inc. 19
recognized roles in regulation of carcino-
genesis function as a double-edged
sword, and AIM2 is no exception. Data
presented here by Man et al. (2015) sug-
gest that AIM2 is necessary to inhibit
cellular, particularly intestinal stem cell,
proliferation in response to carcinogens.
Yet, overexpression of AIM2 can lead
to increased cellular adhesion and inva-
siveness, which may promote metastasis
(Patsos et al., 2010). Therefore, any mod-
ulation of Aim2 expression must be tightly
regulated.
Collectively, the intriguing new insights
offered by Man et al. (2015) group AIM2
with a growing class of colorectal-can-
cer-associated immune sensors (Janow-
ski et al., 2013). Based on their findings,
interrogating how AIM2 acts in concert
with other innate sensors such as
NLRP3, NLRC4, NLRP6, and NLRP12 to
control colorectal cancer may be the
next step forward toward modulation of
the innate immune system for therapeutic
benefit. Nevertheless, in humans, the un-
derlying heterogeneity and inherent na-
ture of cancer as a multifactorial condition20 Cell 162, July 2, 2015 ª2015 Elsevier Inc.in which genetics and environment
impinge upon each other to manifest a
disease that is essentially ‘‘unique’’ from
individual to individual poses a major
challenge for cancer research. Cancer is
an emergent property of the dysregulation
of multiple epigenetic, transcriptional,
molecular, and cellular circuits rather
than the result of a single genetic event.
Examining these multiple scales may
enable a holistic understanding of the un-
derlying factors and/or mechanisms that
promote cancer. The road is long, but
hopefully through relentless research ef-
forts, literal meaning may be imparted to
John Diamond’s words—reducing cancer
to a word that is no longer perceived as a
‘‘sentence.’’
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In this issue of Cell, Langen et al. use time-lapse multiphoton microscopy to show how Drosophila
photoreceptor growth cones find their targets. Based on the observed dynamics, they develop a
simple developmental algorithm recapitulating the highly complex connectivity pattern of these
neurons, suggesting a basic framework for establishing wiring specificity.Large-scale efforts to precisely recon-
struct the connectomes of different visual
systems are uncovering a remarkable
level of complexity. How this elaborate
and precise wiring is established is a crit-
ical question, since the sheer number of
specific connections presents a major
wiring challenge. Design principles com-
mon between vertebrate and insect visual
systems suggest that basic mechanismsfor establishing wiring specificity may be
shared between such distantly related
species (Sanes and Zipursky, 2010).
Using high-resolution time-lapse imaging
and mathematical modeling of fly visual
system neurons, Langen et al. (2015)
(this issue of Cell) define a set of simple
rules that are sufficient for wiring speci-
ficity of these neurons. Hence, a complex
interplay of many specific guidance sig-nals may not always be needed to estab-
lish precise connectivity.
The Drosophila visual system mani-
fests a complex connectivity pattern of
photoreceptor axons in the optic lobe
and has long served as a model for
how individual neurons find their appro-
priate synaptic partners (Hadjieconomou
et al., 2011). The six outer photoreceptor
neurons (R1–6) in each ommatidial unit
